PMC:7102662 / 16112-16952 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T39","span":{"begin":88,"end":96},"obj":"Body_part"},{"id":"T40","span":{"begin":497,"end":506},"obj":"Body_part"}],"attributes":[{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma62338"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T150","span":{"begin":364,"end":373},"obj":"Disease"},{"id":"T151","span":{"begin":693,"end":701},"obj":"Disease"}],"attributes":[{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A151","pred":"mondo_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T97","span":{"begin":68,"end":73},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T98","span":{"begin":410,"end":413},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T99","span":{"begin":523,"end":531},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T100","span":{"begin":744,"end":747},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T101","span":{"begin":760,"end":761},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":523,"end":531},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T134","span":{"begin":0,"end":140},"obj":"Sentence"},{"id":"T135","span":{"begin":141,"end":374},"obj":"Sentence"},{"id":"T136","span":{"begin":375,"end":537},"obj":"Sentence"},{"id":"T137","span":{"begin":538,"end":702},"obj":"Sentence"},{"id":"T138","span":{"begin":703,"end":840},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T267","span":{"begin":80,"end":87},"obj":"UBERON:0000948"},{"id":"T268","span":{"begin":399,"end":409},"obj":"UBERON:0000948"},{"id":"T269","span":{"begin":470,"end":477},"obj":"UBERON:0000948"},{"id":"T270","span":{"begin":693,"end":701},"obj":"SP_7"},{"id":"T28710","span":{"begin":74,"end":79},"obj":"GO:0016265"},{"id":"T28698","span":{"begin":195,"end":202},"obj":"UBERON:0000948"},{"id":"T59720","span":{"begin":297,"end":305},"obj":"SP_7"},{"id":"T39589","span":{"begin":629,"end":636},"obj":"UBERON:0000948"},{"id":"T43336","span":{"begin":656,"end":663},"obj":"UBERON:0000948"},{"id":"T74507","span":{"begin":691,"end":699},"obj":"SP_7"},{"id":"T87124","span":{"begin":793,"end":801},"obj":"UBERON:0001621"},{"id":"T70670","span":{"begin":803,"end":813},"obj":"UBERON:0002349"},{"id":"T13529","span":{"begin":828,"end":833},"obj":"NCBITaxon:10239"},{"id":"T309","span":{"begin":80,"end":87},"obj":"UBERON:0000948"},{"id":"T310","span":{"begin":399,"end":409},"obj":"UBERON:0000948"},{"id":"T311","span":{"begin":470,"end":477},"obj":"UBERON:0000948"},{"id":"T312","span":{"begin":693,"end":701},"obj":"SP_7"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"477","span":{"begin":131,"end":139},"obj":"Species"},{"id":"478","span":{"begin":679,"end":687},"obj":"Species"},{"id":"479","span":{"begin":826,"end":834},"obj":"Species"},{"id":"480","span":{"begin":364,"end":373},"obj":"Disease"},{"id":"481","span":{"begin":693,"end":701},"obj":"Disease"}],"attributes":[{"id":"A477","pred":"tao:has_database_id","subj":"477","obj":"Tax:9606"},{"id":"A478","pred":"tao:has_database_id","subj":"478","obj":"Tax:9606"},{"id":"A479","pred":"tao:has_database_id","subj":"479","obj":"Tax:9606"},{"id":"A480","pred":"tao:has_database_id","subj":"480","obj":"MESH:D007239"},{"id":"A481","pred":"tao:has_database_id","subj":"481","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]."}